Literature DB >> 23979027

TOC1: characterization of a selective oligomeric tau antibody.

Sarah M Ward1, Diana S Himmelstein, Jody K Lancia, Yifan Fu, Kristina R Patterson, Lester I Binder.   

Abstract

The work presented herein addresses a specific portion of the tau pathology, pre-fibrillar oligomers, now thought to be important pathological components in Alzheimer's disease and other neurodegenerative tauopathies. In previous work, we generated an antibody against purified recombinant cross-linked tau dimers, called Tau Oligomeric Complex 1 (TOC1). TOC1 recognizes tau oligomers and its immunoreactivity is elevated in Alzheimer's disease brains. In this report, we expand upon the previous study to show that TOC1 selectively labels tau oligomers over monomers or polymers, and that TOC1 is also reactive in other neurodegenerative tauopathies. Using a series of deletion mutants spanning the tau molecule, we further demonstrate that TOC1 has one continuous epitope located within amino acids 209-224, in the so-called proline rich region. Together with the previous study, our data indicates that TOC1 is a conformation-dependent antibody whose epitope is revealed upon dimerization and oligomerization, but concealed again as polymers form. This characterization of the TOC1 antibody further supports its potential as a powerful biochemical tool that can be used to better investigate the involvement of tau in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979027      PMCID: PMC4791958          DOI: 10.3233/JAD-131235

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  55 in total

1.  Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.

Authors:  G A Jicha; R Bowser; I G Kazam; P Davies
Journal:  J Neurosci Res       Date:  1997-04-15       Impact factor: 4.164

2.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.

Authors:  Bin Zhang; Arpita Maiti; Sharon Shively; Fara Lakhani; Gaye McDonald-Jones; Jennifer Bruce; Edward B Lee; Sharon X Xie; Sonali Joyce; Chi Li; Philip M Toleikis; Virginia M-Y Lee; John Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

3.  Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

Authors:  Martin Ramsden; Linda Kotilinek; Colleen Forster; Jennifer Paulson; Eileen McGowan; Karen SantaCruz; Aaron Guimaraes; Mei Yue; Jada Lewis; George Carlson; Michael Hutton; Karen H Ashe
Journal:  J Neurosci       Date:  2005-11-16       Impact factor: 6.167

4.  Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.

Authors:  Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

5.  Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure.

Authors:  O Schweers; E Schönbrunn-Hanebeck; A Marx; E Mandelkow
Journal:  J Biol Chem       Date:  1994-09-30       Impact factor: 5.157

6.  Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Authors:  Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder
Journal:  J Biol Chem       Date:  2011-05-06       Impact factor: 5.157

7.  Granular tau oligomers as intermediates of tau filaments.

Authors:  Sumihiro Maeda; Naruhiko Sahara; Yuko Saito; Miyuki Murayama; Yuji Yoshiike; Hyonchol Kim; Tomohiro Miyasaka; Shigeo Murayama; Atsushi Ikai; Akihiko Takashima
Journal:  Biochemistry       Date:  2007-03-06       Impact factor: 3.162

8.  Neurons may live for decades with neurofibrillary tangles.

Authors:  R Morsch; W Simon; P D Coleman
Journal:  J Neuropathol Exp Neurol       Date:  1999-02       Impact factor: 3.685

Review 9.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons.

Authors:  Jessica W Wu; Mathieu Herman; Li Liu; Sabrina Simoes; Christopher M Acker; Helen Figueroa; Joshua I Steinberg; Martin Margittai; Rakez Kayed; Chiara Zurzolo; Gilbert Di Paolo; Karen E Duff
Journal:  J Biol Chem       Date:  2012-11-27       Impact factor: 5.157

View more
  27 in total

1.  Tau assembly: the dominant role of PHF6 (VQIVYK) in microtubule binding region repeat R3.

Authors:  Pritam Ganguly; Thanh D Do; Luca Larini; Nichole E LaPointe; Alexander J Sercel; Madeleine F Shade; Stuart C Feinstein; Michael T Bowers; Joan-Emma Shea
Journal:  J Phys Chem B       Date:  2015-03-24       Impact factor: 2.991

2.  TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.

Authors:  Sarah M Ward; Diana S Himmelstein; Yan Ren; Yifan Fu; Xiao-Wen Yu; Kaleigh Roberts; Lester I Binder; Naruhiko Sahara
Journal:  Neurobiol Dis       Date:  2014-03-12       Impact factor: 5.996

3.  Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.

Authors:  Chelsea T Tiernan; Benjamin Combs; Kristine Cox; Gerardo Morfini; Scott T Brady; Scott E Counts; Nicholas M Kanaan
Journal:  Exp Neurol       Date:  2016-06-30       Impact factor: 5.330

4.  Progression of tau pathology within cholinergic nucleus basalis neurons in chronic traumatic encephalopathy: A chronic effects of neurotrauma consortium study.

Authors:  Elliott J Mufson; Sylvia E Perez; Muhammad Nadeem; Laura Mahady; Nicholas M Kanaan; Eric E Abrahamson; Milos D Ikonomovic; Fiona Crawford; Victor Alvarez; Thor Stein; Ann C McKee
Journal:  Brain Inj       Date:  2016       Impact factor: 2.311

5.  Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Authors:  Kristine Cox; Benjamin Combs; Brenda Abdelmesih; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Neurobiol Aging       Date:  2016-07-29       Impact factor: 4.673

6.  Tau and Axonal Transport Misregulation in Tauopathies.

Authors:  Benjamin Combs; Rebecca L Mueller; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

7.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

8.  Pseudomonas aeruginosa exoenzymes U and Y induce a transmissible endothelial proteinopathy.

Authors:  K Adam Morrow; Cristhiaan D Ochoa; Ron Balczon; Chun Zhou; Laura Cauthen; Mikhail Alexeyev; Katherine M Schmalzer; Dara W Frank; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-04       Impact factor: 5.464

9.  Production of recombinant tau oligomers in vitro.

Authors:  Benjamin Combs; Chelsea T Tiernan; Chelsey Hamel; Nicholas M Kanaan
Journal:  Methods Cell Biol       Date:  2017-07-14       Impact factor: 1.441

10.  Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.

Authors:  Nicholas M Kanaan; Kristine Cox; Victor E Alvarez; Thor D Stein; Sharra Poncil; Ann C McKee
Journal:  J Neuropathol Exp Neurol       Date:  2016-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.